Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Lenacapavir/islatravir combo carries mechanistic rationale Mixed oral/subQ regimens don’t provide additional convenience ...

A few days later, confidence in the drug was dented again when Gilead Sciences called a halt to a mid-stage trial of islatravir given alongside its HIV capsid inhibitor lenacapavir, which is ...

namely ViiV Healthcare with cabotegravir and Merck & Co’s islatravir (MK-8591). The 36-patient CAPELLA trial tested lenacapavir in highly treatment-experienced HIV patients who had developed ...

Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form of PrEP. Currently, only one form of long-acting PrEP, taken every two ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. Before filing for global regulatory approvals ...

Lenacapavir, a twice-yearly injectable antiretroviral, reduced the risk of HIV infection by 96% in a large study of gay and bisexual men and gender diverse people, according to a Gilead Sciences ...